Natera Announces Positive Trial Results for Bladder Cancer Treatment, Boosts Stock

Natera Inc announced positive topline results from the IMvigor011 clinical trial in muscle-invasive bladder cancer. The trial used Natera's Signatera ctDNA test to detect molecular residual disease and predict patient response to immunotherapy atezolizumab, resulting in significant improvements in disease-free and overall survival for Signatera-positive patients. Natera plans to present the full trial data and seek FDA premarket approval for Signatera as a companion diagnostic tool. This could enhance Natera's market position in the oncology diagnostics sector and open new revenue streams.

Natera Inc. (NASDAQ: NTRA) has announced positive topline results from the IMvigor011 clinical trial, a phase III study in muscle-invasive bladder cancer (MIBC). The trial utilized Natera's Signatera ctDNA test to detect molecular residual disease (MRD) and predict patient response to immunotherapy atezolizumab, resulting in significant improvements in disease-free and overall survival for Signatera-positive patients.

The IMvigor011 trial, sponsored by Genentech, a member of the Roche Group, enrolled approximately 760 patients who underwent serial Signatera testing for up to 12 months post-surgery. Patients who tested Signatera-positive and remained free of cancer recurrence on imaging were randomized to receive atezolizumab or placebo. Those who consistently tested Signatera-negative were followed up without adjuvant treatment.

Topline results demonstrated a statistically significant and clinically meaningful improvement in disease-free survival and overall survival for Signatera-positive patients treated with atezolizumab. Professor Thomas Powles, lead principal investigator of the study, commented, "The results of IMvigor011 are very significant, opening the door for a new treatment paradigm for bladder cancer patients who are positive for recurrence on a molecular level but have no evidence of disease on imaging." [1]

Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer at Natera, added, "Importantly, IMvigor011 could change how resectable bladder cancer is managed for the tens of thousands of patients diagnosed with MIBC each year." [1]

Natera plans to present the full trial data at an upcoming medical conference and is working to finalize its premarket approval application to the U.S. Food and Drug Administration for Signatera as a companion diagnostic for the selection of MIBC patients to be treated with atezolizumab after cystectomy.

In addition to the topline results, a preliminary analysis of Signatera-negative patients from IMvigor011 was presented at the European Association of Urology in April 2024. The data highlighted excellent outcomes without adjuvant treatment for patients who remained Signatera-negative on serial testing. [2]

The successful results from IMvigor011 could enhance Natera's market position in the oncology diagnostics sector and open new revenue streams. The company's Signatera ctDNA test has been supported by over 300 peer-reviewed publications and operates under ISO 13485-certified and CAP-accredited laboratories. [1]

References:
[1] https://www.biospace.com/press-releases/imvigor011-bladder-cancer-trial-achieves-positive-results-with-signatera-strongly-predicting-adjuvant-immunotherapy-benefit
[2] https://www.morningstar.com/news/business-wire/20250818904141/imvigor011-bladder-cancer-trial-achieves-positive-results-with-signatera-strongly-predicting-adjuvant-immunotherapy-benefit